key: cord-1031860-c5s447oc authors: Lo Caputo, Sergio; Corso, Gaetano; Clerici, Mario; Santantonio, Teresa Antonia title: Baricitinib: A chance to treat COVID‐19? date: 2020-06-02 journal: J Med Virol DOI: 10.1002/jmv.26033 sha: e86ba37a391a49b3079cc3370c5db79af211d1a7 doc_id: 1031860 cord_uid: c5s447oc Currently, there are no approved therapies for the treatment of COVID-19. With most of the world on lockdown and the looming threat of millions of deaths, there is immense pressure to find a therapy for this disease. This article is protected by copyright. All rights reserved. To the Editor, Currently, there are no approved therapies for the treatment of COVID-19. With most of the world on lockdown and the looming threat of millions of deaths, there is immense pressure to find a therapy for this disease. Recently, baricitinib has been proposed as a potential treatment for COVID-19 due to its anti-inflammatory and antiviral activities. 1 In fact, Baricitinib a potent and selective Janus Kinases (JAK) inhibitor currently used in the therapy of rheumatoid arthritis (RA), would likely prevent the dysregulated production of proinflammatory cytokines typically observed in people with Covid-19. 2 Moreover, baricitinib, by binding to AP2-associated protein kinase 1 (AAK1), a pivotal regulator of clathrin-dependent endocytosis, might also inhibit virus entry into target cells. 3 Finally, the oral administration and the minimal interactions with CYP enzymes, make baricitinib one of the most promising drug among those currently available. 4 Herein we report for the first time the favorable clinical course of a patient with a diagnosis of RA who had undergone baricitinib therapy for more than a year and who developed COVID-19. The patient, an 87-year-old woman, was admitted on March 10, to the Infectious Disease Unit, University Hospital of Foggia, Italy with a mild-to-moderate COVID-19. The patient was part of a familiar cluster, as COVID-19 was diagnosed in three other family members (husband, son, and daughter) ( Table 1) . At admission, chest radiography showed the presence of bi-basal infiltrates. Baseline laboratory tests showed lymphopenia, increased C-reactive protein and serum IL-6 concentrations that were increased but still significantly lower compared to those observed in her husband and her son, who also showed increased levels of IL-8, interferon gamma, and monocyte chemoattractant protein-1 ( Table 2 ). The patient received supplemental oxygenation, lopinavir/ritonavir, hydroxychloroquine, while continuing baricitinib. Therapy was successful as she recovered: she is currently apyretic with O 2 saturation 95% in ambient air. In contrast, her husband (90-year-old) and son (59-year-old), who received the same therapy with the exception of baricitinib, showed a rapid disease progression and after few days they died of respiratory failure. Although no conclusion can be drawn from a single case, the favorable course of COVID-19 observed in this patient despite the older age, and the underlying rheumatologic disease, allows to speculate that baricitinib had a positive impact on the outcome. Data herein, although preliminary, support the suggestion to clinically evaluate the use of baricitinib in patients with COVID-19. The patient has given written consent to the processing of their data COVID-19: combining antiviral and anti-inflammatory treatments Clinical features of patients infected with 2019 novel coronavirus in Wuhan Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Olumiant: summary of product characteristics The authors declare that there are no conflict of interests.